DEF 14A: Tharimmune Seeks Stockholder Approval for Reverse Stock Split, Amended Equity Incentive Plan

Tharimmune, Inc. is asking stockholders to vote on key proposals at its upcoming annual meeting, including a reverse stock split to regain Nasdaq compliance and an amended equity incentive plan to attract and retain talent.

Summary

• Tharimmune, Inc. has scheduled its 2024 annual meeting of stockholders for May 14, 2024.
• The meeting will address the election of five directors, ratification of the company's independent auditor (Rosenberg Rich Baker Berman P.A.), and a proposal to grant the board discretionary authority to effect a reverse stock split within a range of 1-for-2 to 1-for-50.
• The reverse stock split aims to increase the company's stock price to meet Nasdaq's minimum bid price requirement.
• Stockholders will also vote on approving the Tharimmune, Inc. Amended and Restated 2023 Omnibus Equity Incentive Plan, which increases the number of shares available for issuance to 2,500,000 and includes an evergreen provision for automatic annual increases.
• The record date for determining stockholders eligible to vote at the meeting was March 21, 2024.
• As of the record date, there were 11,789,676 shares of common stock outstanding.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily conveying factual information about the upcoming shareholder meeting and proposals. The need for a reverse stock split suggests underlying challenges, but the equity incentive plan aims to improve long-term prospects.

Positives

• The reverse stock split could make the company's stock more attractive to institutional investors and improve liquidity.
• The Amended and Restated 2023 Plan is designed to attract, retain, and incentivize key employees, directors, and consultants.
• The board is committed to good corporate governance practices and has established audit, compensation, and nominating and corporate governance committees.
• Three of the five directors are deemed independent, ensuring objective oversight of management.
• The company has adopted a related person transaction policy to ensure fair dealings.

Negatives

• There is no guarantee that the reverse stock split will increase the stock price or maintain Nasdaq compliance.
• A reduction in the number of outstanding shares may impair the liquidity of the common stock.
• The reverse stock split could have an anti-takeover effect by increasing the number of authorized but unissued shares.
• The company has previously been notified by Nasdaq regarding non-compliance with the minimum bid price requirement.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement could result in delisting.
• Other factors, such as financial results and market conditions, could adversely affect the stock price despite the reverse stock split.
• The reverse stock split may not make the common stock a more attractive and cost effective investment for many investors.
• The potential equity dilution from all equity incentive awards outstanding and available for grant under all of our equity plans would result in a maximum potential equity dilution of approximately 18%.

Future Outlook

The company aims to regain compliance with Nasdaq listing requirements through a reverse stock split and to incentivize employees through the Amended and Restated 2023 Plan.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. Equity incentive plans are standard tools for attracting and retaining talent in the competitive biotechnology industry.

Comparison to Industry Standards

• Reverse stock splits are frequently used by companies facing delisting from exchanges, similar to what happened with Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) when Leonard Mazur became CEO.
• The size of the equity incentive plan (2,500,000 shares) is comparable to those of other small-cap biotechnology companies, such as 9 Meters Biopharma, Inc. (Nasdaq: NMTR), where Sireesh Appajosyula serves as SVP, Corporate Development and Operations.
• The annual base salaries and bonus structures for the CEO and COO are within the typical range for executive compensation in similar-sized biopharmaceutical companies, as seen with CorMedix Inc., where Randy Milby previously served as CEO.

Management Changes

Corporate Governance

Related Party Transactions

• At December 31, 2021, the company had accrued compensation to the founder and CEO totaling $200,000, which was paid in full in April 2022.
• On January 4, 2022 and January 6, 2022, the company issued unsecured promissory notes in the aggregate principal amount of $139,000 to three related party investors.
• The notes were repaid in full on January 21, 2022 upon closing of the company's IPO on January 14, 2022.

Stakeholder Impact

• Shareholders: The reverse stock split could impact the value and liquidity of their shares.
• Employees: The Amended and Restated 2023 Plan could provide additional incentives and compensation opportunities.
• Potential Investors: The reverse stock split could make the company's stock more attractive to a broader range of investors.

Next Steps

• Stockholders will vote on the proposals at the annual meeting on May 14, 2024.
• The board will determine the specific ratio for the reverse stock split, if approved.
• The company will file the Reverse Stock Split Amendment with the Delaware Secretary of State, if the board decides to proceed.
• The company will implement the Amended and Restated 2023 Plan, if approved.

Key Dates

Keywords

reverse stock split, proxy statement, annual meeting, equity incentive plan, corporate governance, director election, Nasdaq, compensation, Tharimmune